目的 观察研究灵宝护心丹治疗原发性微血管性心绞痛的临床疗效及安全性。方法 选取2019年12月—2022年6月就诊于南阳市中心医院的原发性微血管性心绞痛患者76例，按随机数字表法分为对照组（38例）和治疗组（38例）。对照组患者给予冠状动脉粥样硬化性心脏病二级预防常规治疗，治疗组在上述治疗基础上口服灵宝护心丹，4粒/次，3次/d。两组患者均连续治疗4周。观察两组患者临床疗效，比较治疗前后两组患者西雅图心绞痛调查量表（SQA）评分、运动平板结果和冠脉血流储备（CFR）。结果 治疗后，治疗组总有效率为92.11%，明显高于对照组（71.05%，P＜0.05）。治疗后，两组SAQ评分在各方面均高于治疗前（P＜0.05），且治疗组显著高于对照组（P＜0.05）。治疗后，两组患者运动平板总运动时间明显升高，而ST段最大压低程度明显下降（P＜0.05），且治疗组患者运动平板结果改善均显著优于对照组（P＜0.05）。治疗后，两组CFR指标比治疗前明显升高（P＜0.05），且治疗组患者冠脉血流储备情况显著高于对照组（P＜0.05）。结论 灵宝护心丹能够改善微血管心绞痛患者的临床症状，提高冠脉血流储备，增强运动耐量并改善患者生活质量。

Objective To observe and study the clinical efficacy and safety of Lingbao Huxindan in the treatment of primary microvascular angina pectoris. Methods Patients (76 cases) with primary microvascular angina pectoris in Nanyang Central Hospital from December 2019 to June 2022 were divided into control (38 cases) and treatment (38 cases) group according to random number table method. Patients in the control group were administered with routine treatment for secondary prevention of coronary atherosclerotic heart disease. Patients in the treatment group were po administered with Lingbao Huxindan on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluations were evaluated, the SAQ scores, exercise treadmill results, and CFR in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 92.11%, which was significantly higher than that of the control group (71.05%, P < 0.05). After treatment, the SAQ score of the two groups was higher than that before treatment (P < 0.05), and which of the treatment group was significantly higher than that of the control group (P < 0.05). After treatment, the total exercise time of treadmill was significantly increased, while the maximum depression of ST was significantly decreased in both groups (P < 0.05), and the improvement of treadmill results in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the CFR index in two groups was significantly higher than that before treatment (P < 0.05), and the coronary flow reserve in the treatment group was significantly higher than that in the control group (P < 0.05). Conclusion Lingbao Huxindan can improve the clinical symptoms of patients with microvascular angina pectoris, increase coronary blood flow reserve, enhance exercise tolerance and improve the quality of life of patients.

R972

国家重点研发计划项目（2018YFC1312400）